Patient reimbursement in therapeutic cancer clinical trials: An 18‐year multicenter experience
Cancer · 15.11.2026 · 132 (22)
DOI: 10.1002/cncr.70625 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer, online erschienen am 09.11.2026. Verfasst von Sukh Makhnoon und 22 weiteren Autor:innen. Beteiligte Einrichtung: Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Neoplasms, Clinical Trials as Topic, Insurance, Health, Reimbursement. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Cancer Prevention and Research Institute of Texas, Robert A. Winn Excellence in Clinical Trials Award Program.
Abstract (Originalsprache)
Background
Clinical trials add to the financial burden of cancer care. To expand equitable access to trials, from 2006 to 2024 the Lazarex Cancer Foundation reimbursed nonmedical expenses related to therapeutic cancer clinical trial participation.
Methods
Eligible patients were enrolled in a cancer treatment trial and had a household income of ≤700% of the federal poverty level. Expense reimbursement occurred at 50%, 75%, and 100% according to income level. This study analyzed the type, timing, and amounts (in 2024 dollars) of reimbursed expenses for trial participants. Associations between patient/trial characteristics, reimbursed amounts, and distance traveled were evaluated via t ‐tests, analysis of variance, and multivariate linear regression.
Results
Overall, 2826 individuals (64% non‐Hispanic White, 97% with health insurance, with a median household income of $50,948) received at least one reimbursement. Median total per‐patient reimbursement was $2128, median trial participation duration was 4.3 months, and monthly reimbursed amounts declined substantially throughout trial participation. Types of reimbursement varied by patient income: internet, ground transportation, and child/elder care were more common at lower income levels, whereas lodging and airfare were more common for higher incomes. In multivariate analysis, monthly reimbursed amount was greater among middle‐tier household income quartiles ( p = .003), greater distance to trial site ( p < .001), and phase 1 trials ( p = .001). The proportion of patients participating across income levels remained stable over time.
Conclusions
Reimbursement needs during cancer clinical trial participation are dynamic and closely tied to both socioeconomic status and logistical burden, particularly travel distance and trial intensity. Financial support for these expenses may enhance trial accessibility and retention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Peter O'Donnell Jr. School of Public Health, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Children's Health, Dallas, Texas, USA.
- Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Lazarex Cancer Foundation, Danville, California, USA.
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Sukh Makhnoon, Puja Umaretiya, Navid Sadeghi, Hala T Borno, David E Gerber
Förderung
- Cancer Prevention and Research Institute of Texas
- Robert A. Winn Excellence in Clinical Trials Award Program
Zitieren
APA
Makhnoon, S., Gao, A., Lee, J. L., Umaretiya, P., Miller, C., Zhang, S., Sridhar, A., Williams, E. L., Dornsife, D. L., Johnson, R. G., Santaniello, A., Bryant, L., Sadeghi, N., Nipp, R. D., Moy, B., Borno, H. T., Zhang, S., Spicer, D. V., Leavey, P. J., …, & Gerber, D. E. (2026). Patient reimbursement in therapeutic cancer clinical trials: An 18‐year multicenter experience. Cancer, 132(22). https://doi.org/10.1002/cncr.70625
Vancouver
Makhnoon S, Gao A, Lee JL, Umaretiya P, Miller C, Zhang S, et al. Patient reimbursement in therapeutic cancer clinical trials: An 18‐year multicenter experience. Cancer. 2026;132(22). doi:10.1002/cncr.70625
BibTeX
@article{Makhnoon2026,
author = {Makhnoon, Sukh and Gao, Ang and Lee, Jessica L and Umaretiya, Puja and Miller, Caitlyn and Zhang, Song and Sridhar, Arthi and Williams, Erin L and Dornsife, Dana L and Johnson, Robert G and Santaniello, Ashley and Bryant, Loren and Sadeghi, Navid and Nipp, Ryan D and Moy, Beverly and Borno, Hala T and Zhang, Sylvia and Spicer, Darcy V and Leavey, Patrick J and Kitzman, Heather E and McNeill, Lorna Haughton and Guerra, Carmen E and Gerber, David E},
title = {Patient reimbursement in therapeutic cancer clinical trials: An 18‐year multicenter experience},
journal = {Cancer},
year = {2026},
volume = {132},
number = {22},
doi = {10.1002/cncr.70625}
}
EUVIMED